Navigation Links
2009 Bush budget a disaster for HIV/AIDS
Date:2/4/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 3Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 4Health News:New York Women's Agenda Presents AUA Foundation Executive Director Sandra Vassos with Star Award 2Health News:New York Women's Agenda Presents AUA Foundation Executive Director Sandra Vassos with Star Award 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 2Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 4Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 1Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 2Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 1Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 2Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 4Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 5ScienceFirst Staff Expansion 58015 1
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 2InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 3InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 4InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 5